Furthermore, sorafenib inhibited the expression of p-Akt and p-ERK1/2 in HCC cells in a dose-dependent manner (Figs. 3c, 4a and Additional file 2: Figure S3A). This evidence concerns the gene AKT1 and hepatocellular carcinoma.